Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization.
Koh Y, Kim DY, Park SH, Jung SH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Shin HJ, Kim SH, Song HS, Chung J, Kim I, Yoon SS, Kim BK, Shin SH, Chung YJ, Park S. Koh Y, et al. Among authors: kim hj, kim dy, kim sh, kim sj, kim bk, kim i. Cancer Genet Cytogenet. 2010 Dec;203(2):215-21. doi: 10.1016/j.cancergencyto.2010.08.022. Cancer Genet Cytogenet. 2010. PMID: 21156236
Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK. Lee KW, et al. Among authors: kim dw, kim dy, kim ty, kim bk, kim nk. Cancer. 2003 Dec 15;98(12):2651-6. doi: 10.1002/cncr.11846. Cancer. 2003. PMID: 14669285 Free article.
Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG. Lee KH, et al. Among authors: kim dy, kim sh. Biol Blood Marrow Transplant. 2009 Jan;15(1):61-72. doi: 10.1016/j.bbmt.2008.10.025. Biol Blood Marrow Transplant. 2009. PMID: 19135944 Free article. Clinical Trial.
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS, Kim HJ, Kim I, Yoon SS, Park S, Bae SH, Bang SM, Lee HG, Shin HJ, Lee JH, Min YH, Won JH, Mun YC, Oh D; Korean Society of Hematology AML/MDS Working Party. Kim DY, et al. Among authors: kim yk, kim hj, kim i. Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19. Ann Hematol. 2010. PMID: 19543727
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party. Koh Y, et al. Among authors: kim cs, kim hj, kim dy, kim sh, kim sj, kim bk, kim i, kim mk. Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24. Ann Hematol. 2010. PMID: 20179930 Clinical Trial.
5,143 results